相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy.
Georgina V. Long et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAFV600 mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.
Grant A. McArthur et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
Christian U. Blank et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study
H. Gogas et al.
ANNALS OF ONCOLOGY (2021)
Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial
R. Dummer et al.
NATURE MEDICINE (2021)
Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
Alexander M. Menzies et al.
NATURE MEDICINE (2021)
Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR A Prospective, Single-arm, Open-label Phase II Trial
Stephanie A. Blankenstein et al.
ANNALS OF SURGERY (2021)
First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.
Christian U. Blank et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
Ralf Gutzmer et al.
LANCET (2020)
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M. D. Hellmann et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert et al.
LANCET ONCOLOGY (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
LBA69Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial
A M Arance et al.
ANNALS OF ONCOLOGY (2019)
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
G V Long et al.
ANNALS OF ONCOLOGY (2019)
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
Reinhard Dummer et al.
LANCET ONCOLOGY (2018)
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial
Rodabe N. Amaria et al.
LANCET ONCOLOGY (2018)
Safety, activity, and biomarkers for neoadjuvant anti-PD-1 therapy in melanoma
Alexander C. Huang et al.
CANCER RESEARCH (2018)
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunilkumar Kakadia et al.
ONCOTARGETS AND THERAPY (2018)
Melanoma and immunotherapy bridge 2015
Vashisht G. Y. Nanda et al.
Journal of Translational Medicine (2016)
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Jing Liu et al.
CANCER DISCOVERY (2016)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
Siwen Hu-Lieskovan et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
G. V. Long et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
James Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Deborah A. Knight et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells
Bishu Sapkota et al.
ONCOIMMUNOLOGY (2013)
BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
Richard C. Koya et al.
CANCER RESEARCH (2012)
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
James S. Wilmott et al.
CLINICAL CANCER RESEARCH (2012)
BRAF inhibition improves tumor recognition by the immune system Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer
Marco Donia et al.
ONCOIMMUNOLOGY (2012)
Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
Andrea Boni et al.
CANCER RESEARCH (2010)